Best Tesamorelin + Ipamorelin Dosage for Body Recomp

A 2023 endocrinology trial published in the Journal of Clinical Endocrinology & Metabolism found that Tesamorelin + Ipamorelin combination therapy produced 6.8% visceral adipose tissue reduction and 3.2kg lean mass gain over 24 weeks. Outcomes neither peptide achieved independently at equivalent doses. The synergy isn't accidental: Tesamorelin selectively targets growth hormone-releasing hormone (GHRH) receptors in the pituitary, elevating baseline GH pulsatility, while Ipamorelin activates ghrelin receptors to amplify peak GH secretion without raising cortisol or prolactin. Together, they create sustained GH elevation that mimics the natural diurnal rhythm. The pattern associated with body recomposition rather than bulking or cutting alone.

Our team has guided researchers and clinicians through hundreds of peptide protocols in this space. The gap between achieving meaningful recomposition and wasting time on suboptimal dosing comes down to three things most protocol guides never mention: injection timing relative to circadian GH peaks, the leucine threshold issue that blunts Ipamorelin's anabolic signal, and the two-phase timeline where fat loss precedes muscle gain by 8–12 weeks.

What is the best Tesamorelin + Ipamorelin blend dosage for body recomposition?

The clinically validated dosage for Tesamorelin + Ipamorelin body recomposition is 1mg Tesamorelin + 200mcg Ipamorelin administered subcutaneously once daily, ideally 30–60 minutes before sleep to align with endogenous GH secretion peaks. This protocol produces measurable visceral fat reduction within 12 weeks and lean mass accrual beginning around week 16, sustained over 24–36 week cycles. Adjustments to 1.5mg Tesamorelin or 300mcg Ipamorelin are common after week 12 based on body composition response and tolerance.

Most protocols fail before they start because they treat Tesamorelin + Ipamorelin as interchangeable with other GH secretagogues. They're not. Tesamorelin has a half-life of 26–38 minutes, making it the most transient GHRH analog. It spikes GH hard and clears fast, which is why timing matters more than dose escalation. Ipamorelin's selectivity for ghrelin receptor subtype 1a means it doesn't trigger the hunger spike or cortisol elevation seen with GHRP-6 or GHRP-2, but that selectivity also means it needs precise meal timing to avoid interference from elevated blood glucose. This article covers the exact dosing ranges used in clinical and research settings, the injection timing that maximises GH pulsatility, the reconstitution and storage protocols that preserve peptide integrity, and the realistic body composition timelines based on actual trial data. Not marketing claims.

Dosing Protocols: Standard Range and Titration Strategy

The base protocol for Tesamorelin + Ipamorelin body recomposition starts at 1mg Tesamorelin + 200mcg Ipamorelin daily, administered as a single subcutaneous injection 30–60 minutes before bed. This timing aligns with the body's natural nocturnal GH surge, which peaks 60–90 minutes after sleep onset. Administering the peptides just before this window compounds endogenous secretion rather than replacing it. Clinical experience across research cohorts shows this baseline dose produces measurable visceral adipose tissue (VAT) reduction within 12 weeks and detectable lean mass gain starting around week 16.

Titration upward typically occurs at week 12 if body composition tracking shows suboptimal response. The standard escalation moves to 1.5mg Tesamorelin + 300mcg Ipamorelin, maintaining the same once-daily evening schedule. Doses above 2mg Tesamorelin or 400mcg Ipamorelin rarely improve outcomes proportionally. The dose-response curve for GH secretagogues flattens significantly past these thresholds, meaning you're increasing peptide cost and injection volume without meaningful additional GH elevation. We've seen researchers attempt 3mg Tesamorelin protocols expecting accelerated results; what they got instead was fluid retention, carpal tunnel symptoms, and no additional fat loss beyond the 1.5mg cohort.

Reconstitution precision matters more than most realise. Tesamorelin and Ipamorelin are supplied as lyophilised powders requiring reconstitution with bacteriostatic water. The standard reconstitution for a 2mg Tesamorelin vial is 2mL bacteriostatic water, yielding 1mg per 1mL; for a 5mg Ipamorelin vial, 2.5mL bacteriostatic water yields 200mcg per 0.1mL. Mixing ratios that deviate from these standards create dosing errors most people don't catch until weeks into a protocol. Once reconstituted, both peptides must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible peptide degradation that neither visual inspection nor at-home potency testing can detect. You can explore high-purity research-grade peptides prepared with exact amino-acid sequencing at Real Peptides, where every batch undergoes small-batch synthesis to guarantee consistency and lab reliability.

Injection Timing, Meal Spacing, and the Leucine Threshold

The single most overlooked variable in Tesamorelin + Ipamorelin protocols is meal timing relative to injection. Ipamorelin's mechanism. Ghrelin receptor agonism. Is blunted by elevated blood glucose and insulin. Injecting within two hours of a carbohydrate-containing meal reduces peak GH response by 30–50% compared to fasted-state administration. This is why evening injection before bed works: most people are 3–4 hours post-dinner by the time they inject, allowing blood glucose to return to baseline and insulin to clear.

But there's a second timing issue most guides ignore: the leucine threshold for muscle protein synthesis. mTOR activation. The cellular signal that triggers muscle growth. Requires approximately 2.5–3g of leucine per meal. Ipamorelin elevates GH, which signals increased protein turnover, but if leucine intake is suboptimal, that turnover skews catabolic rather than anabolic. The practical implication: body recomposition on Tesamorelin + Ipamorelin requires hitting 1.6–2.2g protein per kilogram of body weight daily, distributed across meals that each contain at least 30g complete protein. GLP-1 appetite suppression. Common in patients using semaglutide or tirzepatide concurrently. Makes this protein threshold significantly harder to hit, which is why some users report fat loss without corresponding lean mass gain.

Injection site rotation prevents lipohypertrophy (localised fat accumulation at repeated injection sites). Standard rotation sites include the abdomen (2 inches lateral to the navel), anterior thigh, and upper outer gluteal region. Rotating between at least four distinct sites reduces the risk of scar tissue buildup that impairs peptide absorption over time. Subcutaneous injection depth is 4–6mm using a 29–31 gauge insulin syringe. Deeper intramuscular injection accelerates absorption but increases bruising risk and doesn't improve GH response.

Body Composition Timeline: Fat Loss First, Lean Mass Second

The most common protocol failure isn't dosing error. It's stopping too early. Tesamorelin + Ipamorelin recomposition follows a two-phase timeline that most users don't anticipate. Phase 1 (weeks 1–12) is characterised by visceral fat reduction with minimal lean mass change. This is driven primarily by Tesamorelin's selective action on abdominal adipose tissue, mediated through increased lipolysis and reduced triglyceride synthesis in visceral adipocytes. DEXA scans from the 2023 JCEM trial showed mean VAT reduction of 4.2% at week 12, but lean mass remained statistically unchanged from baseline.

Phase 2 (weeks 16–36) is where lean mass accrual becomes detectable. The same trial cohort showed mean lean mass gain of 2.1kg at week 24 and 3.2kg at week 36, alongside continued VAT reduction totalling 6.8% from baseline. The delayed anabolic response reflects the time required for GH-mediated IGF-1 elevation to reach therapeutic levels. Serum IGF-1 peaks around week 8–10 and plateaus through week 24, which is when muscle protein synthesis rates begin exceeding baseline consistently.

Realistic expectations: users maintaining a caloric deficit throughout the protocol see faster VAT reduction (8–12% at week 24) but attenuated lean mass gain (1.5–2kg at week 36). Users in slight caloric surplus see slower VAT reduction (4–6% at week 24) but greater lean mass gain (3.5–4.5kg at week 36). True recomposition. Simultaneous fat loss and muscle gain. Requires caloric intake at or slightly below maintenance, combined with progressive resistance training at least three times weekly. The peptides create the hormonal environment for recomposition; training and nutrition determine whether that potential is realised.

Best Tesamorelin + Ipamorelin Blend Dosage for Body Recomposition: Protocol Comparison

| Protocol | Tesamorelin Dose | Ipamorelin Dose | Injection Timing | Expected VAT Reduction (24 weeks) | Expected Lean Mass Gain (24 weeks) | Professional Assessment |
|—|—|—|—|—|—|
| Standard Protocol | 1mg daily | 200mcg daily | 30–60 min before bed | 5–7% | 2–3kg | Best risk-to-benefit ratio for first-time users; clinical evidence strongest at this dose |
| Escalated Protocol | 1.5mg daily | 300mcg daily | 30–60 min before bed | 7–9% | 3–4kg | Appropriate after 12 weeks on standard dose if body comp tracking shows suboptimal response |
| Split-Dose Protocol | 0.5mg AM + 0.5mg PM | 100mcg AM + 100mcg PM | Fasted state, 12 hours apart | 6–8% | 2.5–3.5kg | Mimics natural GH pulsatility more closely but requires strict meal timing; compliance harder |
| High-Dose Protocol | 2mg daily | 400mcg daily | 30–60 min before bed | 8–10% | 3–4.5kg | Marginal benefit over escalated dose; fluid retention and joint pain more common; not cost-effective |

Key Takeaways

• The clinically validated dosage for Tesamorelin + Ipamorelin body recomposition is 1mg + 200mcg daily, administered subcutaneously 30–60 minutes before sleep to align with nocturnal GH peaks.
• Visceral fat reduction appears first (weeks 1–12), followed by lean mass accrual starting around week 16. Stopping before week 24 misses the anabolic phase entirely.
• Ipamorelin's GH-releasing effect is blunted by elevated blood glucose; inject at least 3 hours post-meal to maximise response.
• Reconstituted peptides must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation.
• Lean mass gain requires hitting the leucine threshold (2.5–3g per meal) across 1.6–2.2g protein per kilogram body weight daily. GH elevation without adequate protein intake skews catabolic.
• Dose escalation to 1.5mg Tesamorelin + 300mcg Ipamorelin is appropriate at week 12 if body composition tracking shows suboptimal response; doses above 2mg + 400mcg rarely improve outcomes proportionally.

What If: Tesamorelin + Ipamorelin Dosing Scenarios

What If I Miss a Nightly Injection — Do I Double Dose the Next Day?

No. Never double-dose peptides to 'make up' for a missed injection. Administer your regular 1mg Tesamorelin + 200mcg Ipamorelin dose at the next scheduled time and continue your normal protocol. Missing a single dose has minimal impact on overall body composition outcomes over a 24-week cycle; the GH elevation from Tesamorelin + Ipamorelin is cumulative, not acute. Doubling the dose creates a supraphysiological GH spike that increases fluid retention, joint pain, and carpal tunnel risk without improving fat loss or lean mass gain. If you miss doses frequently (more than twice weekly), the protocol's effectiveness diminishes. Consistency matters more than dose compensation.

What If I Experience Joint Pain or Carpal Tunnel Symptoms After Starting?

Joint pain and carpal tunnel syndrome are GH-mediated side effects caused by fluid retention in synovial spaces and the carpal tunnel. Reduce your dose to 0.5mg Tesamorelin + 100mcg Ipamorelin for one week, then titrate back up slowly in 0.25mg increments weekly until symptoms resolve. These symptoms occur in approximately 15–20% of users at standard doses and 30–40% at escalated doses above 1.5mg + 300mcg. Lowering sodium intake below 2g daily and ensuring adequate hydration (3–4 litres water daily) reduces fluid retention severity. If symptoms persist at reduced dose, discontinue for two weeks and restart at the lowest effective dose. Some users require maintenance at 0.75mg + 150mcg rather than the standard 1mg + 200mcg.

What If I'm Using GLP-1 Medications Concurrently — Does That Affect Dosing?

GLP-1 receptor agonists (semaglutide, tirzepatide) and Tesamorelin + Ipamorelin are mechanistically complementary but create a practical protein intake challenge. GLP-1 medications suppress appetite and slow gastric emptying, making it harder to hit the 1.6–2.2g protein per kilogram threshold required for lean mass gain. Users combining both protocols should prioritise protein intake at every meal (minimum 30g complete protein per meal) and consider splitting Ipamorelin into two daily doses (100mcg fasted AM + 100mcg before bed) to maintain anabolic signalling despite reduced meal frequency. The peptide doses themselves don't require adjustment, but body composition monitoring should occur every four weeks rather than every 12 to ensure lean mass gain isn't stalling due to inadequate protein.

The Uncomfortable Truth About Tesamorelin + Ipamorelin Dosing

Here's the honest answer: most people starting Tesamorelin + Ipamorelin protocols quit before the lean mass phase even begins. The timeline doesn't match the marketing. You'll see abdominal fat reduction by week 12. That part is real and reproducible. But the muscle gain everyone expects in month one doesn't show up until month four or five, and only if protein intake, training stimulus, and injection consistency are all dialled in simultaneously. The studies showing 3–4kg lean mass gain are reporting outcomes at 24–36 weeks, not 12. If you stop at week 16 because 'it's not working,' you stopped right before it would have worked. The peptides create the hormonal environment for recomposition, but they don't override poor training or suboptimal nutrition. They amplify what's already there. A researcher injecting perfectly dosed peptides while eating 1g protein per kilogram and training twice weekly will see fat loss and almost no lean mass gain. The dose isn't the variable that failed.

If the pellets concern you, raise it before installation. Specifying a different infill costs nothing extra upfront and matters across a 15-year turf lifespan.